Plasma IP-10 and IL-6 Are Linked to Child-Pugh B Cirrhosis in Patients with Advanced HCV-related Cirrhosis: a Cross-sectional Study

Overview

Journal Sci Rep

Specialty Science

Date 2020 Jun 27

PMID 32587340

Citations 4

Authors

Sergio Salguero

Luz Maria Medrano

Juan Gonzalez-Garcia

Juan Berenguer

Maria L Montes

Cristina Diez

Pilar Garcia-Broncano

Elba Llop-Herrera

Leire Perez-Latorre

Jose Maria Bellono

Maria Angeles Jimenez-Sousa

Salvador Resino

Affiliations

Soon will be listed here.

Abstract

We aimed to evaluate the association of plasma biomarkers linked to inflammation (bacterial translocation, inflammatory response, and endothelial dysfunction), coagulopathy, and angiogenesis with the severity of liver cirrhosis (assessed by the Child-Pugh-Turcotte score, CTP) and Child-Pugh B cirrhosis (CTP 7-9) in patients with advanced hepatitis C virus (HCV)-related cirrhosis. We carried out a cross-sectional study in 97 patients with advanced HCV-related cirrhosis (32 HCV-monoinfected and 65 HIV/HCV-coinfected). Plasma biomarkers were measured by ProcartaPlex multiplex immunoassays. The outcome variable was the CTP score and the Child-Pugh B cirrhosis (CTP 7-9). HIV/HCV-coinfected patients and HCV-monoinfected patients with advanced HCV-related cirrhosis had near-equivalent values of plasma biomarkers. Higher values of plasma biomarkers linked to an inflammatory response (IP-10, IL-8, IL-6, and OPG), endothelial dysfunction (sVCAM-1 and sICAM-1), and coagulopathy (D-dimer) were related to higher CTP values. The most significant biomarkers to detect the presence of Child-Pugh B cirrhosis (CTP 7-9) were IP-10 (p-value= 0.008) and IL-6 (p-value=0.002). The AUC-ROC values of IP-10, IL-6, and both biomarkers combined (IP-10+IL-6) were 0.78, 0.88, and 0.96, respectively. In conclusion, HIV infection does not appear to have a significant impact on the analyzed plasma biomarkers in patients with advanced HCV-related cirrhosis. However, plasma biomarkers linked to inflammation (inflammatory response and endothelial dysfunction) were related to the severity of liver cirrhosis (CTP score), mainly IP-10 and IL-6, which discriminated patients with Child-Pugh B concerning Child-Pugh A.

Citing Articles

Artificial intelligence-based evaluation of prognosis in cirrhosis.

Zhai Y, Hai D, Zeng L, Lin C, Tan X, Mo Z J Transl Med. 2024; 22(1):933.

PMID: 39402630 PMC: 11475999. DOI: 10.1186/s12967-024-05726-2.

Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis-Pathogenesis, Implications and Therapeutic Opportunities.

Terbah R, Testro A, Gow P, Majumdar A, Sinclair M Nutrients. 2024; 16(1).

PMID: 38201864 PMC: 10780673. DOI: 10.3390/nu16010035.

Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis.

Rey I, Effendi-Ys R Med Arch. 2021; 75(3):199-203.

PMID: 34483450 PMC: 8385729. DOI: 10.5455/medarh.2021.75.199-203.

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.

Medrano L, Berenguer J, Salguero S, Gonzalez-Garcia J, Diez C, Hontanon V Front Med (Lausanne). 2021; 8:615342.

PMID: 33598470 PMC: 7882604. DOI: 10.3389/fmed.2021.615342.

References

Westbrook R, Dusheiko G . Natural history of hepatitis C. J Hepatol. 2014; 61(1 Suppl):S58-68. DOI: 10.1016/j.jhep.2014.07.012. View

Naggie S . Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. Top Antivir Med. 2017; 25(1):3-6. PMC: 5677037. View

Shin E, Sung P, Park S . Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016; 16(8):509-23. DOI: 10.1038/nri.2016.69. View

Irvine K, Ratnasekera I, Powell E, Hume D . Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol. 2019; 10:293. PMC: 6401613. DOI: 10.3389/fimmu.2019.00293. View

Albillos A, Lario M, Alvarez-Mon M . Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 61(6):1385-96. DOI: 10.1016/j.jhep.2014.08.010. View

Gonzalez-Reimers E, Quintero-Platt G, Martin-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F . Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol. 2016; 22(18):4427-37. PMC: 4858626. DOI: 10.3748/wjg.v22.i18.4427. View

Koziel M, Peters M . Viral hepatitis in HIV infection. N Engl J Med. 2007; 356(14):1445-54. PMC: 4144044. DOI: 10.1056/NEJMra065142. View

Lopez-Dieguez M, Montes M, Pascual-Pareja J, Quereda C, von Wichmann M, Berenguer J . The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011; 25(7):899-904. DOI: 10.1097/QAD.0b013e3283454174. View

Macias J, Berenguer J, Japon M, Giron J, Rivero A, Lopez-Cortes L . Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009; 50(4):1056-63. DOI: 10.1002/hep.23136. View

10.

Del Campo J, Gallego P, Grande L . Role of inflammatory response in liver diseases: Therapeutic strategies. World J Hepatol. 2018; 10(1):1-7. PMC: 5787673. DOI: 10.4254/wjh.v10.i1.1. View

11.

Hunt P, Lee S, Siedner M . Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016; 214 Suppl 2:S44-50. PMC: 5021241. DOI: 10.1093/infdis/jiw275. View

12.

Hunt P . HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012; 9(2):139-47. DOI: 10.1007/s11904-012-0118-8. View

13.

Kostadinova L, Shive C, Zebrowski E, Fuller B, Rife K, Hirsch A . Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathog Immun. 2018; 3(1):149-163. PMC: 6201254. DOI: 10.20411/pai.v3i1.242. View

14.

Macias J, Granados R, Tellez F, Merino D, Perez M, Morano L . Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. J Viral Hepat. 2018; 26(1):16-24. DOI: 10.1111/jvh.12990. View

15.

Lopez-Cortes L, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo O, Dominguez-Molina B, Milanes-Guisado Y . Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018; 218(4):624-632. DOI: 10.1093/infdis/jiy136. View

16.

Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer A . Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology. 2019; 71(3):1023-1036. PMC: 7155089. DOI: 10.1002/hep.30885. View

17.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P . Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016; 65(4):727-733. DOI: 10.1016/j.jhep.2016.06.015. View

18.

Medrano L, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, Jimenez-Sousa M, Guardiola J . Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. AIDS. 2018; 32(9):1095-1105. DOI: 10.1097/QAD.0000000000001787. View

19.

Durand F, Valla D . Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005; 42 Suppl(1):S100-7. DOI: 10.1016/j.jhep.2004.11.015. View

20.

Breen E, Tan W, Khan A . The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays. Sci Rep. 2016; 6:26996. PMC: 4886638. DOI: 10.1038/srep26996. View